
X4 Pharmaceuticals, Inc — Investor Relations & Filings
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-12 | English | |
| S-3 - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | |
| 10-Q - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | |
| ARS - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | |
| DEFA14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | |
| DEF 14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 45339551 | 8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-12 | English | ||
| 42006962 | S-3 - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | ||
| 41806531 | 10-Q - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-05-06 | English | ||
| 32999251 | ARS - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | ||
| 32999249 | DEFA14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | ||
| 32999239 | DEF 14A - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-20 | English | ||
| 32963514 | 10-K - X4 Pharmaceuticals, Inc (0001501697) (Filer) | 2026-03-17 | English | ||
| 30181392 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30181257 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30181249 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 30181231 | SCHEDULE 13G Filing | 2026-02-17 | English | ||
| 30181103 | SCHEDULE 13G/A Filing | 2026-02-13 | English | ||
| 30181313 | SCHEDULE 13G/A Filing | 2026-02-05 | English | ||
| 30181211 | SCHEDULE 13G/A Filing | 2026-01-15 | English | ||
| 12390315 | FORM 4 | 2026-01-07 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Ambrilia Biopharma Inc.
Biopharmaceutical company focused on novel treatments for o…
|
AMB | CA | Manufacturing |
|
AMGEN INC
A biotechnology company developing human therapeutics for s…
|
AMGN | US | Manufacturing |
|
Amicogen, Inc.
Industrial biotechnology company specializing in specialty …
|
092040 | KR | Manufacturing |
|
AMICUS THERAPEUTICS, INC.
Biotechnology company developing therapies for rare genetic…
|
FOLD | US | Manufacturing |
|
AMINOLOGICS CO.,LTD.
Specialty manufacturer of high-purity chiral amino acids an…
|
074430 | KR | Manufacturing |
|
Amneal Pharmaceuticals, Inc.
Develops, manufactures, and distributes generic and special…
|
AMRX | US | Manufacturing |
|
Amoy Diagnostics Co.,Ltd.
Develops molecular diagnostic kits and companion diagnostic…
|
300685 | CN | Manufacturing |
|
Amphastar Pharmaceuticals, Inc.
Develops, manufactures, and markets technically challenging…
|
AMPH | US | Manufacturing |
|
Amrutanjan Health Care Limited
Develops and distributes over-the-counter healthcare and pe…
|
AMRUTANJAN | IN | Manufacturing |
|
Amwill Health Care Limited
Develops, manufactures, and distributes a wide range of med…
|
544353 | IN | Manufacturing |
X4 Pharmaceuticals, Inc via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34355/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34355 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34355 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34355 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34355}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for X4 Pharmaceuticals, Inc (id: 34355)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.